Sai Parenteral's IPO Update: GMP Compliance, Subscription Statistics, and Investor Guidance on Second Trading Day

Sai Parenteral's IPO Update

Subscription Status The initial public offering (IPO) of Sai Parenteral's, a diversified pharmaceutical formulations company, closed with a subscription of just 0.05 times on March 26. The issue was subscribed 3.35 lakh shares against 72.99 lakh shares on offer. The retail portion was subscribed 0.03 times, while the non-institutional investor (NII) portion was subscribed 0.15 times.

Grey Market Premium The grey market premium (GMP) for Sai Parenteral's is ₹0 on March 25, indicating a muted investor sentiment towards the IPO. This suggests that the stock is likely to debut at ₹392, the same as the IPO price.

IPO Details The ₹409 crore IPO is a combination of a fresh issue of 0.73 crore shares aggregating to ₹285 crore and an offer for sale (OFS) of 0.32 crore shares aggregating to ₹123.79 crore. The company plans to utilise the proceeds from the fresh issue for capacity expansion, upgradation of manufacturing facilities, establishment of a new R&D centre, and debt repayment.

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Valuation According to Swastika Investmart, the valuation of Sai Parenteral's appears stretched at a pre-IPO P/E of 72.19x and RoCE of only 9.28%. However, the company's business fundamentals and growth trajectory are solid, with a long-term growth thesis supported by its WHO-GMP and TGA-accredited facilities.

Brokerage Recommendations Swastika Investmart recommends that investors seeking short-term or listing gains avoid the IPO, citing an unfavorable risk-reward ratio. SBI Securities, on the other hand, recommends investors subscribe to the Sai Parenteral's IPO at the cut-off price for a long-term investment horizon.